Millipore Sigma Vibrant Logo

AB9668 Anti-Tau phospho Threonine 231 Antibody

View Products on Sigmaaldrich.com
AB9668
100 µL  
Ricerca del prezzo in corso...
Non è stato possibile trovare il prezzo
La quantità minima deve essere un multiplo di
Maximum Quantity is
Al termine dell'ordine Maggiori informazioni
Lei ha salvato ()
 
Richiedi il prezzo
Disponibilità limitata
Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

      Offerte speciali

       

      Contatti il Servizio Clienti

      Panoramica

      Replacement Information

      Offerte speciali

      Tabella delle specifiche principali

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWBRbAffinity PurifiedPolyclonal Antibody
      Description
      Catalogue NumberAB9668
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Tau phospho Threonine 231 Antibody
      Background InformationTau is a neuronal microtubule-associated protein found predominantly on axons and functions to promote tubulin polymerization and stabilize microtubules. Tau, in its hyperphosphorylated form, is the major component of paired helical filaments (PHF), the building block of neurofibrillary lesions in Alzheimer's disease (AD) brain. Hyperphosphorylated Tau is also found in neurofibrillary lesions in a range of other central nervous system disorders. Hyperphosphorylation impairs the microtubule binding function of Tau, resulting in the destabilization of microtubules in AD brains, ultimately leading to the degeneration of the affected neurons. Numerous serine/threonine kinases, including GSK-3beta, protein kinase A (PKA), cyclin-dependent kinase 5 (cdk5) and casein kinase II (CK2), phosphorylate Tau. Threonine 231 is phosphorylated by GSK-3beta, cdk5 and cdk1 and has been shown to be involved in the pre-tangle process of AD.
      References
      Product Information
      FormatAffinity Purified
      PresentationAffinity purified immunoglobulin. Liquid in Dulbecco's PBS (without Mg2+ and Ca2+), pH 7.3, 50% glycerol with 1.0 mg/mL BSA and 0.05% sodium azide.
      Quality LevelMQ100
      Applications
      ApplicationAnti-Tau phospho Threonine 231 Antibody detects level of Tau phospho Threonine 231 & has been published & validated for use in WB.
      Key Applications
      • Western Blotting
      Application NotesWestern blot: 1:1,000. Suggested blocking buffer is 5% BSA-TBST for one hour at room temperature. Suggested antibody dilution buffer is 1% BSA-TBST. Suggested antibody incubation time is 2 hours at room temperature..

      Optimal working dilutions must be determined by the end user.
      Biological Information
      ImmunogenSynthetic peptide of amino acids surrounding the phosphoThreonine 231 site of human Tau.
      HostRabbit
      SpecificityTau phosphoThreonine 231. The antibody recognizes Tau pThreonine 231 in samples of recombinant human Tau treated with GSK-3beta for 45 minutes. The reactivity of the antibody is blocked with the pThreonine 231 peptide but not the non-phosphopeptide or a generic phosphoThreonine-containing peptide.
      Species Reactivity
      • Human
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
      Gene Symbol
      • MAPT
      • MTBT2
      • MAPTL
      • PHF-tau
      • tau
      • DDPAC
      • FTDP-17
      • MGC138549
      • MSTD
      • TAU
      • FLJ31424
      • MTBT1
      • PPND
      Modifications
      • Phosphorylation
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P10636 # Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
      SIZE: 758 amino acids; 78878 Da
      SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.
      SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
      TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
      DOMAIN: SwissProt: P10636 The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
      PTM: Phosphorylation at serine and threonine residues in S-P or T- P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K- X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser- 622, Ser-641 and Ser-673 in several isoforms during mitosis. & Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur. & Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
      DISEASE: SwissProt: P10636 # In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). & Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also called frontotemporal dementia (FTD) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. & Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia. & Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. & Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson- Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. & Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.
      SIMILARITY: Contains 4 Tau/MAP repeats.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain at -20°C in undiluted for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles. Do not store in a self defrosting freezer.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      AB9668 04053252337000

      Documentation

      Anti-Tau phospho Threonine 231 Antibody MSDS

      Titolo

      Scheda di sicurezza (MSDS) 

      Anti-Tau phospho Threonine 231 Antibody Certificati d'Analisi

      TitoloNumero di lotto
      Anti-Tau phospho Threonine 23 - 2117253 2117253
      Anti-Tau phospho Threonine 231 - 2123661 2123661
      Anti-Tau phospho Threonine 231 - 2143477 2143477
      Anti-Tau phospho Threonine 231 - 1992655 1992655
      Anti-Tau phospho Threonine 231 - 2002183 2002183
      Anti-Tau phospho Threonine 231 - 2058951 2058951
      Anti-Tau phospho Threonine 231 - 2062319 2062319
      Anti-Tau phospho Threonine 231 - 2266738 2266738
      Anti-Tau phospho Threonine 231 - 2501477 2501477
      Anti-Tau phospho Threonine 231 - 3231925 3231925

      Riferimenti bibliografici

      Panoramica dei riferimenti bibliograficiCodice d'identificazione nel Pub Med
      Pericyte loss influences Alzheimer-like neurodegeneration in mice.
      Sagare, AP; Bell, RD; Zhao, Z; Ma, Q; Winkler, EA; Ramanathan, A; Zlokovic, BV
      Nature communications  4  2932  2013

      Mostra il sommario
      24336108 24336108
      Increased Tau Phosphorylation and Impaired Brain Insulin/IGF Signaling in Mice Fed a High Fat/High Cholesterol Diet.
      Bhat, Narayan R and Thirumangalakudi, Lakshmi
      J. Alzheimers Dis., (2013)  2013

      Mostra il sommario
      23703152 23703152
      Dephosphorylation of Tau by protein phosphatase 5: impairment in Alzheimer's disease.
      Liu, F., et al.
      J. Biol. Chem., 280(3):1790-1796 (2005)  2004

      15546861 15546861
      The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation.
      Jämsä, A., et al.
      Biochem. Biophys. Res. Comm., 319:993-1000 (2004)  2004

      15184080 15184080
      O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
      Liu, Fei, et al.
      Proc. Natl. Acad. Sci. U.S.A., 101: 10804-9 (2004)  2004

      Mostra il sommario
      15249677 15249677
      Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.
      Augustinack, J.C., et al.
      Acta Neuropathol., 103:26-35 (2002)  2002

      11837744 11837744
      Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice.
      Sawamura, N, et al.
      J. Biol. Chem., 276: 10314-9 (2001)  2001

      Mostra il sommario
      11152466 11152466
      Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice.
      Tesseur,I., et al.
      Am. J. Pathol., 156(3):951-964 (2000)  1999

      10702411 10702411
      Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.
      Gong, C.X., et al.
      J. Biol. Chem., 275(8):5535-5544 (2000)  1999

      10681533 10681533
      Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase.
      Wang, J.Z., et al.
      FEBS Lett., 436(1):28-34 (1998)  1998

      9771888 9771888

      Newsletters / Publications

      Title
      Research Focus - Volume 2, 2013

      Prodotti e applicazioni correlate

      Linee di prodotti

      Categorie

      Life Science Research > Antibodies and Assays > Primary Antibodies